These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37555463)

  • 1. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
    Lück HJ; Schmidt M; Hesse T; Hoffmann O; Heinrich BJ; Park-Simon TW; Grischke EM; Weide R; Müller-Huesmann H; Lüdtke-Heckenkamp K; Fischer D; Zemlin C; Kögel M; Wu J; Schmitz H; Engelbrecht C; Jackisch C
    Oncologist; 2023 Dec; 28(12):e1152-e1159. PubMed ID: 37555463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
    Vahdat LT; Garcia AA; Vogel C; Pellegrino C; Lindquist DL; Iannotti N; Gopalakrishna P; Sparano JA
    Breast Cancer Res Treat; 2013 Jul; 140(2):341-51. PubMed ID: 23877339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
    Tsurutani J; Sakata Y; Matsuoka T
    Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
    Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
    Acta Oncol; 2015 Apr; 54(4):522-9. PubMed ID: 25383448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
    BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    La Verde N; Damia G; Garrone O; Santini D; Fabi A; Ciccarese M; Generali DG; Nunzi M; Poletto E; Ferraris E; Cretella E; Scandurra G; Meattini I; Bertolini AS; Cavanna L; Collovà E; Romagnoli E; Rulli E; Legramandi L; Guffanti F; Bramati A; Moretti A; Cassano A; Vici P; Torri V; Farina G;
    Breast Cancer Res; 2022 Oct; 24(1):71. PubMed ID: 36307826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
    Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
    Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
    Wozniak KM; Wu Y; Farah MH; Littlefield BA; Nomoto K; Slusher BS
    Neurotox Res; 2013 Oct; 24(3):338-44. PubMed ID: 23637052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.
    Zhao B; Zhao H; Zhao J
    Crit Rev Oncol Hematol; 2018 Aug; 128():110-117. PubMed ID: 29958626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
    Wu Y; Wang Q; Zhang J; Cao J; Wang B; Hu X
    Support Care Cancer; 2020 Aug; 28(8):3819-3829. PubMed ID: 31832821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
    McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
    Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study.
    Kenny L; Beresford M; Brown I; Misra V; Kristeleit H
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13747. PubMed ID: 36336468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.